ArticleFrontiers in pharmacology2025
Pharmacological basis for medicinal use of
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Applications of Selected Nanoencapsulated Indigenous Essential Oils in Medicine, Food, and Agriculture: A Review.Foods (Basel, Switzerland) · 2026Review
- Green Synthesis of Titanium Dioxide Nanoparticles: Characterization and Evaluation of Their Potential for Photocatalytic and Dielectric Applications.Molecules (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cymbopogon is used in traditional medicine in tropical and subtropical regions to treat various ailments. However, no research has yet provided a detailed pharmacodynamic explanation for its antidiarrheal and antispasmodic effects. This study aimed to evaluate the antidiarrheal and antispasmodic properties of the essential oil of Methods: An animal study of antidiarrheal activity was carried out using a castor oil-induced diarrhea model in rats, and the isolated small intestine of rats was used to investigate the specific mechanisms of the antispasmodic effects. Results: The EOCP, exhibited a protective effect against castor oil-induced diarrhea in rats at 100 and 200 mg/kg, similar to the standard drug, dicyclomine. In rat ileum preparations, EOCP decreased the basal tonus with a maximal response of (R Conclusion: These results suggest that EOCP produces antidiarrheal and antispasmodic effects, possibly mediated via direct effect on intestinal smooth musclesf followed by dual inhibition of muscarinic receptors and Ca
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.